首页 > 最新文献

European Journal of Internal Medicine最新文献

英文 中文
"Obesity management in the older age, new understanding for old challenges". "老年肥胖症管理,旧挑战新认识"。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.1016/j.ejim.2024.10.023
Dror Dicker, Nursel Çalık Başaran, Volkan Demirhan Yumuk
{"title":"\"Obesity management in the older age, new understanding for old challenges\".","authors":"Dror Dicker, Nursel Çalık Başaran, Volkan Demirhan Yumuk","doi":"10.1016/j.ejim.2024.10.023","DOIUrl":"https://doi.org/10.1016/j.ejim.2024.10.023","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and outcomes of Takotsubo syndrome in patients with chronic obstructive pulmonary disease. 慢性阻塞性肺病患者塔克次氏综合征的临床特征和预后。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.1016/j.ejim.2024.10.026
Luca Arcari, Giacomo Tini, Michela Zuccanti, Giovanni Camastra, Alessandro Cianca, Emanuela Belmonte, Giulio Montefusco, Riccardo Scirpa, Claudia Malerba, Fabrizio Lupparelli, Matteo Sclafani, Viviana Maestrini, Beatrice Musumeci, Emanuele Barbato, Luca Cacciotti

Background: takotsubo syndrome (TTS) is an acute heart failure syndrome characterized by a relevant comorbid background, including chronic obstructive pulmonary disease (COPD). However, TTS patients with COPD are still not well characterized.

Aim: to describe the clinical characteristics and outcomes of patients with TTS and COPD.

Methods: n = 440 TTS patients were dichotomized according to the presence of COPD. Endpoint of the study were in-hospital complications (composite of death, major arrhythmias, cardiogenic shock and acute pulmonary edema), TTS recurrence and long-term mortality at follow-up.

Results: mean age of the population was 72±11, 10 % males. COPD prevalence was 16 % (n = 69). On subgroup analysis, patients with COPD were more likely smokers (41 % vs 13 %, p < 0.001), with higher rates of dyspnea and physical triggers at presentation (52 % vs 18 %, p < 0.001 and 52 % vs 32 %, p = 0.001 respectively) and lower left ventricular ejection fraction (36 % vs 39 %, p = 0.035) In-hospital complications were more common in patients with COPD (26 % vs 13 %, p = 0.006), driven by higher rates of acute pulmonary edema (19 % vs 6 %, p < 0.001) and cardiogenic shock (10 % vs 4 %, p = 0.023). At multivariable logistic regression analysis, COPD was independently associated with in-hospital complications occurrence (Odds Ratio 2.10, 95 % CI 1.09-4.05; p = 0.027). At univariable Cox regression analysis COPD was associated with TTS recurrence (Hazard Ratio (HR 9.82, 95 % CI 3.2-30.12; p < 0.001)), at multivariable Cox regression analysis with long-term mortality (HR 2.97, 95 % CI 1.44-6.12; p = 0.003).

Conclusion: COPD marks a vulnerable TTS phenotype including higher risk of in-hospital complications, long-term recurrence and mortality.

背景:Takotsubo 综合征(TTS)是一种急性心力衰竭综合征,具有相关的合并症背景,包括慢性阻塞性肺疾病(COPD)。目的:描述 TTS 和 COPD 患者的临床特征和预后。方法:根据是否存在 COPD 对 n = 440 名 TTS 患者进行二分法。研究终点为院内并发症(死亡、严重心律失常、心源性休克和急性肺水肿的综合)、TTS复发和随访时的长期死亡率。慢性阻塞性肺病发病率为 16%(n = 69)。亚组分析显示,慢性阻塞性肺病患者更可能是吸烟者(41 % vs 13 %,p < 0.001),发病时呼吸困难和身体诱因的比例更高(分别为 52 % vs 18 %,p < 0.001 和 52 % vs 32 %,p = 0.001),左心室射血分数更低(36 % vs 39 %,p = 0.035)慢性阻塞性肺病患者的院内并发症更常见(26 % vs 13 %,p = 0.006),原因是急性肺水肿(19 % vs 6 %,p < 0.001)和心源性休克(10 % vs 4 %,p = 0.023)的发生率更高。在多变量逻辑回归分析中,慢性阻塞性肺病与院内并发症的发生有独立关联(Odds Ratio 2.10,95 % CI 1.09-4.05;p = 0.027)。在单变量 Cox 回归分析中,慢性阻塞性肺病与 TTS 复发相关(危险比 (HR 9.82, 95 % CI 3.2-30.12; p < 0.001)),在多变量 Cox 回归分析中与长期死亡率相关(HR 2.97, 95 % CI 1.44-6.12; p = 0.003):结论:慢性阻塞性肺病标志着一种脆弱的 TTS 表型,包括较高的院内并发症、长期复发和死亡率风险。
{"title":"Clinical characteristics and outcomes of Takotsubo syndrome in patients with chronic obstructive pulmonary disease.","authors":"Luca Arcari, Giacomo Tini, Michela Zuccanti, Giovanni Camastra, Alessandro Cianca, Emanuela Belmonte, Giulio Montefusco, Riccardo Scirpa, Claudia Malerba, Fabrizio Lupparelli, Matteo Sclafani, Viviana Maestrini, Beatrice Musumeci, Emanuele Barbato, Luca Cacciotti","doi":"10.1016/j.ejim.2024.10.026","DOIUrl":"https://doi.org/10.1016/j.ejim.2024.10.026","url":null,"abstract":"<p><strong>Background: </strong>takotsubo syndrome (TTS) is an acute heart failure syndrome characterized by a relevant comorbid background, including chronic obstructive pulmonary disease (COPD). However, TTS patients with COPD are still not well characterized.</p><p><strong>Aim: </strong>to describe the clinical characteristics and outcomes of patients with TTS and COPD.</p><p><strong>Methods: </strong>n = 440 TTS patients were dichotomized according to the presence of COPD. Endpoint of the study were in-hospital complications (composite of death, major arrhythmias, cardiogenic shock and acute pulmonary edema), TTS recurrence and long-term mortality at follow-up.</p><p><strong>Results: </strong>mean age of the population was 72±11, 10 % males. COPD prevalence was 16 % (n = 69). On subgroup analysis, patients with COPD were more likely smokers (41 % vs 13 %, p < 0.001), with higher rates of dyspnea and physical triggers at presentation (52 % vs 18 %, p < 0.001 and 52 % vs 32 %, p = 0.001 respectively) and lower left ventricular ejection fraction (36 % vs 39 %, p = 0.035) In-hospital complications were more common in patients with COPD (26 % vs 13 %, p = 0.006), driven by higher rates of acute pulmonary edema (19 % vs 6 %, p < 0.001) and cardiogenic shock (10 % vs 4 %, p = 0.023). At multivariable logistic regression analysis, COPD was independently associated with in-hospital complications occurrence (Odds Ratio 2.10, 95 % CI 1.09-4.05; p = 0.027). At univariable Cox regression analysis COPD was associated with TTS recurrence (Hazard Ratio (HR 9.82, 95 % CI 3.2-30.12; p < 0.001)), at multivariable Cox regression analysis with long-term mortality (HR 2.97, 95 % CI 1.44-6.12; p = 0.003).</p><p><strong>Conclusion: </strong>COPD marks a vulnerable TTS phenotype including higher risk of in-hospital complications, long-term recurrence and mortality.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modifiable lifestyle factors in the primordial prevention of hypertension in three US cohorts. 美国三个队列中可改变的生活方式因素对高血压的初步预防作用。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 DOI: 10.1016/j.ejim.2024.10.028
Rikuta Hamaya, Molin Wang, Ellen Hertzmark, Nancy R Cook, JoAnn E Manson, Qi Sun, Meir J Stampfer, Kenneth J Mukamal, Gary Curhan, Eric B Rimm

Background: Evidence is lacking on the relative contributions of specific lifestyle factors and their overall contribution to prevention of hypertension, in particular early-onset hypertension.

Methods: This prospective cohort study included participants of the Nurses' Health Study (NHS, N = 52,780 women, aged 40-67 in 1986), the NHS II (N = 83,871 women, aged 27-46 in 1991), and the Health Professionals Follow-up Study (HPFS, N = 31,269 men, aged 40-75 in 1986), who were free from hypertension, cardiovascular disease and cancer at baseline. Four modifiable lifestyles were evaluated based on hypertension guidelines: BMI, moderate-to-vigorous physical activity, Dietary Approaches to Stop Hypertension (DASH) score, and alcohol intake. Primary outcome was incident self-reported diagnosis of hypertension with 27-31 years of follow-up.

Results: Each lifestyle factor was associated with incident hypertension in dose-dependent manners across the cohorts, with BMI having the strongest associations. On average, adhering to BMI <25 kg/m2 was associated with 20.3 [18.5, 22.0], 25.0 [23.2, 26.8], and 18.6 [16.7, 20.7] months longer periods free from hypertension during 25-year follow-up in each cohort respectively. BMI accounted for approximately 20 % of incident hypertension in NHS and HPFS, and 35 % of early-onset hypertension (age < 55 y). Moderate-to-vigorous physical activity and diet accounted for 10-15 % of incident hypertension in women, and the contributions were greater for early-onset hypertension.

Conclusion: Healthy weight during adulthood was most substantially associated with incident hypertension among lifestyle factors, but diet, physical activity, and alcohol intake were also related to the risk across all ages, and hypertension-free periods, with stronger associations in early-onset hypertension.

背景:关于特定生活方式因素的相对贡献及其对预防高血压(尤其是早发性高血压)的总体贡献,目前还缺乏证据:这项前瞻性队列研究包括护士健康研究(NHS,N = 52,780 名女性,1986 年年龄为 40-67 岁)、护士健康研究 II(N = 83,871 名女性,1991 年年龄为 27-46 岁)和健康专业人员随访研究(HPFS,N = 31,269 名男性,1986 年年龄为 40-75 岁)的参与者,他们在基线时没有高血压、心血管疾病和癌症。根据高血压指南,对四种可改变的生活方式进行了评估:体重指数(BMI)、中度至剧烈运动、饮食疗法(DASH)评分和酒精摄入量。主要结果是在 27-31 年的随访中自我报告的高血压诊断事件:结果:在所有队列中,每个生活方式因素都与高血压的发生有剂量依赖关系,其中与体重指数的关系最为密切。平均而言,在 25 年的随访过程中,坚持体重指数 2 与高血压发生率的相关性分别为 20.3 [18.5, 22.0]、25.0 [23.2, 26.8]和 18.6 [16.7, 20.7]个月。在NHS和HPFS中,BMI约占高血压发病率的20%,占早发性高血压(年龄小于55岁)的35%。适度到剧烈的体育锻炼和饮食占女性高血压发病率的10%-15%,对早发性高血压的影响更大:结论:在生活方式因素中,成年期健康体重与高血压发病率的关系最为密切,但饮食、体育锻炼和酒精摄入也与所有年龄段和无高血压期的风险有关,与早发性高血压的关系更为密切。
{"title":"Modifiable lifestyle factors in the primordial prevention of hypertension in three US cohorts.","authors":"Rikuta Hamaya, Molin Wang, Ellen Hertzmark, Nancy R Cook, JoAnn E Manson, Qi Sun, Meir J Stampfer, Kenneth J Mukamal, Gary Curhan, Eric B Rimm","doi":"10.1016/j.ejim.2024.10.028","DOIUrl":"https://doi.org/10.1016/j.ejim.2024.10.028","url":null,"abstract":"<p><strong>Background: </strong>Evidence is lacking on the relative contributions of specific lifestyle factors and their overall contribution to prevention of hypertension, in particular early-onset hypertension.</p><p><strong>Methods: </strong>This prospective cohort study included participants of the Nurses' Health Study (NHS, N = 52,780 women, aged 40-67 in 1986), the NHS II (N = 83,871 women, aged 27-46 in 1991), and the Health Professionals Follow-up Study (HPFS, N = 31,269 men, aged 40-75 in 1986), who were free from hypertension, cardiovascular disease and cancer at baseline. Four modifiable lifestyles were evaluated based on hypertension guidelines: BMI, moderate-to-vigorous physical activity, Dietary Approaches to Stop Hypertension (DASH) score, and alcohol intake. Primary outcome was incident self-reported diagnosis of hypertension with 27-31 years of follow-up.</p><p><strong>Results: </strong>Each lifestyle factor was associated with incident hypertension in dose-dependent manners across the cohorts, with BMI having the strongest associations. On average, adhering to BMI <25 kg/m<sup>2</sup> was associated with 20.3 [18.5, 22.0], 25.0 [23.2, 26.8], and 18.6 [16.7, 20.7] months longer periods free from hypertension during 25-year follow-up in each cohort respectively. BMI accounted for approximately 20 % of incident hypertension in NHS and HPFS, and 35 % of early-onset hypertension (age < 55 y). Moderate-to-vigorous physical activity and diet accounted for 10-15 % of incident hypertension in women, and the contributions were greater for early-onset hypertension.</p><p><strong>Conclusion: </strong>Healthy weight during adulthood was most substantially associated with incident hypertension among lifestyle factors, but diet, physical activity, and alcohol intake were also related to the risk across all ages, and hypertension-free periods, with stronger associations in early-onset hypertension.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology. 大型类风湿性关节炎队列中对 2019 ESC/EAS 血脂异常管理指南的遵守情况:意大利风湿病学会 CORDIS 研究小组的数据。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-05 DOI: 10.1016/j.ejim.2024.10.029
Fabio Cacciapaglia, Francesca Romana Spinelli, Gian Luca Erre, Matteo Piga, Garifallia Sakellariou, Andreina Manfredi, Marco Fornaro, Ombretta Viapiana, Simone Perniola, Elisa Gremese, Fabiola Atzeni, Elena Bartoloni

Background/aim: Lipid-lowering therapy prescription is low in rheumatoid arthritis (RA) patients, often not achieving lipid threshold target despite treatment. However, evidence derives from small, monocentric cohorts. We assessed adherence to lipid-lowering treatment for primary cardiovascular (CV) prevention in a RA cohort according to international guidelines.

Methods: A cross-sectional analysis of an Italian RA cohort was performed. Disease-related features and traditional CV risk factors were collected. The 10-year CV risk was estimated by Systematic COronary Risk Evaluation 2 (SCORE-2) algorithm. The primary preventive dyslipidaemia strategy was assessed according to 2019 European Society of Cardiology/European Atherosclerosis Society guidelines.

Results: 1.133 RA patients (78.2% female, aged 60.6±10.2 years) free from CV events were included. According to SCORE-2, 42.9% of patients were at moderate risk (1-5-%), 33.3% at high risk (5-10%) and 23.7% at very high risk (>10%). In the whole cohort, 12.9% of patients with <5%, 23.6% with 5-10% and 32.3% with >10% risk were on statin, respectively (p<0.001). According to 2019 ESC/EAS guidelines, 51.5% of patients had LDL-c at target. Among patients with LDL-c not at target, 76% were not on lipid-lowering treatment. At multivariate analysis, patients with higher CV risk had significantly lower probability of LDL-c at target.

Conclusion: In a wide Italian RA cohort, more than 50% of patients had high or very high CV risk. In these, lipid-lowering treatment prescription is suboptimal leading to not achievement of LDL-c target. Physicians should improve lipid screening and primary prevention therapy to reduce CV risk and improve CV comorbidity in RA patients.

背景/目的:类风湿性关节炎(RA)患者的降脂治疗处方量较低,尽管接受了治疗,但往往达不到血脂阈值目标。然而,这些证据均来自小型、单一的队列。我们根据国际指南评估了RA队列中坚持降脂治疗以进行心血管(CV)一级预防的情况:我们对一个意大利 RA 队列进行了横断面分析。收集了疾病相关特征和传统的心血管风险因素。通过系统性冠状动脉风险评估 2(SCORE-2)算法估算了 10 年的冠状动脉风险。根据2019年欧洲心脏病学会/欧洲动脉粥样硬化学会指南评估了一级预防血脂异常策略:共纳入 1.133 名未发生过心血管事件的 RA 患者(78.2% 为女性,年龄为 60.6±10.2 岁)。根据SCORE-2,42.9%的患者为中度风险(1-5-%),33.3%为高度风险(5-10%),23.7%为非常高度风险(>10%)。在整个队列中,10%风险的患者中分别有12.9%在服用他汀类药物(P结论:在一个广泛的意大利 RA 队列中,50% 以上的患者有较高或极高的心血管疾病风险。在这些患者中,降脂治疗处方并不理想,导致无法实现低密度脂蛋白胆固醇目标。医生应改善血脂筛查和一级预防治疗,以降低心血管风险并改善 RA 患者的心血管并发症。
{"title":"Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology.","authors":"Fabio Cacciapaglia, Francesca Romana Spinelli, Gian Luca Erre, Matteo Piga, Garifallia Sakellariou, Andreina Manfredi, Marco Fornaro, Ombretta Viapiana, Simone Perniola, Elisa Gremese, Fabiola Atzeni, Elena Bartoloni","doi":"10.1016/j.ejim.2024.10.029","DOIUrl":"https://doi.org/10.1016/j.ejim.2024.10.029","url":null,"abstract":"<p><strong>Background/aim: </strong>Lipid-lowering therapy prescription is low in rheumatoid arthritis (RA) patients, often not achieving lipid threshold target despite treatment. However, evidence derives from small, monocentric cohorts. We assessed adherence to lipid-lowering treatment for primary cardiovascular (CV) prevention in a RA cohort according to international guidelines.</p><p><strong>Methods: </strong>A cross-sectional analysis of an Italian RA cohort was performed. Disease-related features and traditional CV risk factors were collected. The 10-year CV risk was estimated by Systematic COronary Risk Evaluation 2 (SCORE-2) algorithm. The primary preventive dyslipidaemia strategy was assessed according to 2019 European Society of Cardiology/European Atherosclerosis Society guidelines.</p><p><strong>Results: </strong>1.133 RA patients (78.2% female, aged 60.6±10.2 years) free from CV events were included. According to SCORE-2, 42.9% of patients were at moderate risk (1-5-%), 33.3% at high risk (5-10%) and 23.7% at very high risk (>10%). In the whole cohort, 12.9% of patients with <5%, 23.6% with 5-10% and 32.3% with >10% risk were on statin, respectively (p<0.001). According to 2019 ESC/EAS guidelines, 51.5% of patients had LDL-c at target. Among patients with LDL-c not at target, 76% were not on lipid-lowering treatment. At multivariate analysis, patients with higher CV risk had significantly lower probability of LDL-c at target.</p><p><strong>Conclusion: </strong>In a wide Italian RA cohort, more than 50% of patients had high or very high CV risk. In these, lipid-lowering treatment prescription is suboptimal leading to not achievement of LDL-c target. Physicians should improve lipid screening and primary prevention therapy to reduce CV risk and improve CV comorbidity in RA patients.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The new ESC 2024 guidelines on the management of peripheral arterial and aortic diseases: Lights and shadows. 新版ESC 2024外周动脉和主动脉疾病管理指南:光与影。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-05 DOI: 10.1016/j.ejim.2024.10.025
Claudio Cimminiello, Mauro Molteni
{"title":"The new ESC 2024 guidelines on the management of peripheral arterial and aortic diseases: Lights and shadows.","authors":"Claudio Cimminiello, Mauro Molteni","doi":"10.1016/j.ejim.2024.10.025","DOIUrl":"https://doi.org/10.1016/j.ejim.2024.10.025","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New strategies for the treatment of hyperkalemia. 治疗高钾血症的新策略。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-02 DOI: 10.1016/j.ejim.2024.10.016
Stefano Masi, Herman Dalpiaz, Sara Piludu, Federica Piani, Giulia Fiorini, Claudio Borghi

Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are key drugs in the management of patients with cardiovascular diseases (CVD), particularly those with hypertension, diabetes, chronic kidney disease and heart failure (HF), given their demonstrated effectiveness in reducing the risk of both surrogate and hard endpoints. Despite their positive impact on the outcome, patients with RAASi and MRAs are particularly vulnerable to hyperkalaemia, with approximately 50 % of these individuals experiencing two or more recurrences annually. The common practice of reducing the dose or discontinuing the treatment with RAASi and MRAs in conditions of hyperkalaemia results in suboptimal management of these patients, with a potential impact on their mortality and morbidity risk. Recent guidelines from cardiovascular and renal international societies increasingly recognize the need for alternative strategies to manage the risk of hyperkalaemia, allowing the continuation of RAASi and MRA therapies. In this review, we summarise the new potential options available to manage hyperkalaemia in patients with CVD and the recommendations of the most recent guidelines on the topic.

肾素-血管紧张素-醛固酮系统抑制剂(RAASi)和矿物质皮质激素受体拮抗剂(MRAs)是治疗心血管疾病(CVD)患者,尤其是高血压、糖尿病、慢性肾病和心力衰竭(HF)患者的关键药物,因为它们在降低代偿终点和硬终点的风险方面具有明显的疗效。尽管 RAASi 和 MRA 对疗效有积极影响,但患者特别容易出现高钾血症,其中约 50% 的患者每年会出现两次或两次以上的高钾血症复发。在出现高钾血症的情况下,减少 RAASi 和 MRAs 的剂量或停止治疗的常见做法会导致对这些患者的管理不尽如人意,从而对他们的死亡率和发病率风险产生潜在影响。最近,国际心血管和肾脏协会的指导方针越来越认识到,需要采取替代策略来控制高钾血症的风险,允许继续使用 RAASi 和 MRA 治疗。在本综述中,我们总结了可用于控制心血管疾病患者高钾血症的新的潜在方案,以及最新指南对该主题的建议。
{"title":"New strategies for the treatment of hyperkalemia.","authors":"Stefano Masi, Herman Dalpiaz, Sara Piludu, Federica Piani, Giulia Fiorini, Claudio Borghi","doi":"10.1016/j.ejim.2024.10.016","DOIUrl":"https://doi.org/10.1016/j.ejim.2024.10.016","url":null,"abstract":"<p><p>Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are key drugs in the management of patients with cardiovascular diseases (CVD), particularly those with hypertension, diabetes, chronic kidney disease and heart failure (HF), given their demonstrated effectiveness in reducing the risk of both surrogate and hard endpoints. Despite their positive impact on the outcome, patients with RAASi and MRAs are particularly vulnerable to hyperkalaemia, with approximately 50 % of these individuals experiencing two or more recurrences annually. The common practice of reducing the dose or discontinuing the treatment with RAASi and MRAs in conditions of hyperkalaemia results in suboptimal management of these patients, with a potential impact on their mortality and morbidity risk. Recent guidelines from cardiovascular and renal international societies increasingly recognize the need for alternative strategies to manage the risk of hyperkalaemia, allowing the continuation of RAASi and MRA therapies. In this review, we summarise the new potential options available to manage hyperkalaemia in patients with CVD and the recommendations of the most recent guidelines on the topic.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behaviour therapy for obesity in older adults. 针对老年人肥胖症的行为疗法。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-01 DOI: 10.1016/j.ejim.2024.10.022
Meltem Koca, Laurence J Dobbie, Andreea Ciudin, Meltem Halil

Obesity presents a significant public health challenge, with a growing prevalence among older adults and addressing obesity in older adults presents unique challenges. Behaviour therapy is a cornerstone in obesity management, yet its application in older populations, is underexplored. This narrative review, based on the current literature, examines the role of behavioural change techniques (BCTs) in addressing obesity in older adults, highlighting the need for tailored interventions that consider age-related challenges. BCTs are integral in promoting long-term behaviour change, enhancing self-management, and ensuring adherence to treatment plans. While existing evidence suggests the efficacy of several BCTs such as self-monitoring, goal setting, motivational interviewing, and social support in obesity management, further research is needed to understand their impact in older age groups with multimorbidity and combinations of geriatric syndromes. The impact of these techniques may vary based on factors such as patients' clinical features, cognitive function, sensory deficits, social factors and psychological aspects unique to aging individuals. Therefore, the design and implementation of BCTs in this population require careful evaluation and customization. Tailored interventions that consider the unique needs of this population, such as preserving muscle mass and addressing functional limitations, are essential. Future research should focus on large-scale, well-designed trials to elucidate the optimal BCTs for older individuals, ensuring interventions are diverse and inclusive to meet the needs of older adults with obesity.

肥胖症是一项重大的公共卫生挑战,在老年人中的发病率越来越高,解决老年人的肥胖问题是一项独特的挑战。行为疗法是肥胖症治疗的基石,但其在老年人群中的应用尚未得到充分探索。这篇叙述性综述以现有文献为基础,探讨了行为改变技术(BCTs)在解决老年人肥胖问题中的作用,强调了考虑到与年龄相关的挑战而采取针对性干预措施的必要性。行为改变技术在促进长期行为改变、加强自我管理和确保坚持治疗计划方面不可或缺。虽然现有证据表明,自我监控、目标设定、动机访谈和社会支持等几种BCT在肥胖管理中具有一定的疗效,但还需要进一步研究,以了解它们对患有多病和多种老年综合症的老年群体的影响。这些技术的影响可能因患者的临床特征、认知功能、感官缺陷、社会因素和老年人特有的心理方面等因素而异。因此,在这一人群中设计和实施 BCT 需要仔细评估和量身定制。考虑到这一人群的独特需求(如保持肌肉质量和解决功能限制)的定制干预措施至关重要。未来的研究应侧重于大规模、精心设计的试验,以阐明针对老年人的最佳 BCT,确保干预措施的多样性和包容性,以满足肥胖老年人的需求。
{"title":"Behaviour therapy for obesity in older adults.","authors":"Meltem Koca, Laurence J Dobbie, Andreea Ciudin, Meltem Halil","doi":"10.1016/j.ejim.2024.10.022","DOIUrl":"https://doi.org/10.1016/j.ejim.2024.10.022","url":null,"abstract":"<p><p>Obesity presents a significant public health challenge, with a growing prevalence among older adults and addressing obesity in older adults presents unique challenges. Behaviour therapy is a cornerstone in obesity management, yet its application in older populations, is underexplored. This narrative review, based on the current literature, examines the role of behavioural change techniques (BCTs) in addressing obesity in older adults, highlighting the need for tailored interventions that consider age-related challenges. BCTs are integral in promoting long-term behaviour change, enhancing self-management, and ensuring adherence to treatment plans. While existing evidence suggests the efficacy of several BCTs such as self-monitoring, goal setting, motivational interviewing, and social support in obesity management, further research is needed to understand their impact in older age groups with multimorbidity and combinations of geriatric syndromes. The impact of these techniques may vary based on factors such as patients' clinical features, cognitive function, sensory deficits, social factors and psychological aspects unique to aging individuals. Therefore, the design and implementation of BCTs in this population require careful evaluation and customization. Tailored interventions that consider the unique needs of this population, such as preserving muscle mass and addressing functional limitations, are essential. Future research should focus on large-scale, well-designed trials to elucidate the optimal BCTs for older individuals, ensuring interventions are diverse and inclusive to meet the needs of older adults with obesity.</p>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution and outcomes of aortic dilations in giant cell arteritis 巨细胞动脉炎主动脉扩张的演变和结果。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-01 DOI: 10.1016/j.ejim.2024.03.038

Objectives

To identify factors associated with the progression of giant cell arteritis (GCA)-related or associated aortic dilations.

Methods

In this retrospective study, 47 GCA patients with aortic dilation were longitudinally analyzed. Each patient underwent ≥2 imaging scans of the aorta during the follow-up. Three progression statuses of aortic dilations were distinguished: fast-progressive (FP) defined by a progression of the aortic diameter ≥5 mm/year or ≥1 cm/2 years, slow progressive (SP) by a progression of the aortic diameter >1 mm during the follow-up, and not progressive (NP) when aortic diameter remained stable.

Results

Among the 47 patients with aortic dilation, the thoracic section was involved in 87 % of patients. Within a total follow-up of 89 [6–272] months, we identified 13 (28 %) patients with FP dilations, and 16 (34 %) and 18 (38 %) patients with SP and NP dilations, respectively. No differences regarding baseline characteristics, cardiovascular risk factors or treatments were observed among the 3 groups. However, FP patients more frequently showed atheromatous disease (p = 0.04), with a more frequent use of statins (p = 0.04) and antiplatelet agents (p = 0.02). Among the 27 (57 %) patients with aortitis, aortic dilation developed on an inflammatory segment in 23 (85 %). Among the FP patients who underwent aortic surgery with available histology (n = 3), all presented active vasculitis.

Conclusion

This study suggests that aortic inflammation, as well as atheromatous disease, might participate in the fast progression of aortic dilation in GCA.
方法在这项回顾性研究中,对 47 名主动脉扩张的 GCA 患者进行了纵向分析。每位患者在随访期间接受了≥2次主动脉成像扫描。主动脉扩张有三种进展状态:快速进展(FP)指主动脉直径进展≥5毫米/年或≥1厘米/2年;缓慢进展(SP)指随访期间主动脉直径进展>1毫米;非进展(NP)指主动脉直径保持稳定。在89个月[6-272]的随访中,我们发现13例(28%)患者为FP扩张,16例(34%)和18例(38%)患者为SP和NP扩张。三组患者的基线特征、心血管风险因素或治疗方法均无差异。不过,FP 患者更常出现动脉粥样硬化疾病(p = 0.04),更常使用他汀类药物(p = 0.04)和抗血小板药物(p = 0.02)。在 27 名(57%)主动脉炎患者中,23 名(85%)患者的主动脉扩张发生在炎症部位。结论本研究表明,主动脉炎症和动脉粥样硬化性疾病可能参与了 GCA 主动脉扩张的快速进展。
{"title":"Evolution and outcomes of aortic dilations in giant cell arteritis","authors":"","doi":"10.1016/j.ejim.2024.03.038","DOIUrl":"10.1016/j.ejim.2024.03.038","url":null,"abstract":"<div><h3>Objectives</h3><div>To identify factors associated with the progression of giant cell arteritis (GCA)-related or associated aortic dilations.</div></div><div><h3>Methods</h3><div>In this retrospective study, 47 GCA patients with aortic dilation were longitudinally analyzed. Each patient underwent ≥2 imaging scans of the aorta during the follow-up. Three progression statuses of aortic dilations were distinguished: fast-progressive (FP) defined by a progression of the aortic diameter ≥5 mm/year or ≥1 cm/2 years, slow progressive (SP) by a progression of the aortic diameter &gt;1 mm during the follow-up, and not progressive (NP) when aortic diameter remained stable.</div></div><div><h3>Results</h3><div>Among the 47 patients with aortic dilation, the thoracic section was involved in 87 % of patients. Within a total follow-up of 89 [6–272] months, we identified 13 (28 %) patients with FP dilations, and 16 (34 %) and 18 (38 %) patients with SP and NP dilations, respectively. No differences regarding baseline characteristics, cardiovascular risk factors or treatments were observed among the 3 groups. However, FP patients more frequently showed atheromatous disease (<em>p</em> = 0.04), with a more frequent use of statins (<em>p</em> = 0.04) and antiplatelet agents (<em>p</em><span> = 0.02). Among the 27 (57 %) patients with aortitis, aortic dilation developed on an inflammatory segment in 23 (85 %). Among the FP patients who underwent aortic surgery with available histology (</span><em>n</em> = 3), all presented active vasculitis.</div></div><div><h3>Conclusion</h3><div>This study suggests that aortic inflammation, as well as atheromatous disease, might participate in the fast progression of aortic dilation in GCA.</div></div>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"129 ","pages":"Pages 71-77"},"PeriodicalIF":5.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment 与左心疾病相关的肺动脉高压:表型与治疗
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-01 DOI: 10.1016/j.ejim.2024.07.030
Rosalinda Madonna , Filippo Biondi , Sandra Ghelardoni , Alberto D'Alleva , Stefano Quarta , Marika Massaro
Pulmonary hypertension associated to left heart disease (PH-LHD) refers to a clinical and haemodynamic condition of pulmonary hypertension associated with a heterogeneous group of diseases affecting any of the compartments that form the left ventricle and left atrium. PH-LHD is the most common cause of PH, accounting for 65–80 % of diagnoses. Based on the haemodynamic phase of the disease, PH-LDH is classified into three subgroups: postcapillary PH, isolated postcapillary PH and combined pre-postcapillary PH (CpcPH). Several signaling pathways involved in the regulation of vascular tone are dysfunctional in PH-LHD, including nitric oxide, MAP kinase and endothelin-1 pathways.
These pathways are the same as those altered in PH group 1, however PH-LHD can heardly be treated by specific drugs that act on the pulmonary circulation.
In this manuscript we provide a state of the art of the available clinical trials investigating the safety and efficacy of PAH-specific drugs, as well as drugs active in patients with heart failure and PH-LHD. We also discuss the different phenotypes of PH-LHD, as well as molecular targets and signaling pathways potentially involved in the pathophysiology of the disease. Finally we will mention some new emerging therapies that can be used to treat this form of PH.
与左心疾病相关的肺动脉高压(PH-LHD)是指肺动脉高压的一种临床和血流动力学症状,与一组影响左心室和左心房任何部分的异质性疾病相关。PH-LHD 是 PH 最常见的病因,占诊断病例的 65-80%。根据疾病的血流动力学阶段,PH-LDH 可分为三个亚组:毛细血管后 PH、孤立毛细血管后 PH 和合并毛细血管前 PH(CpcPH)。在 PH-LDH 中,一些参与调节血管张力的信号通路出现功能障碍,包括一氧化氮、MAP 激酶和内皮素-1 通路。这些通路与 PH 组 1 中发生改变的通路相同,但 PH-LHD 可通过作用于肺循环的特定药物进行治疗。在本手稿中,我们介绍了现有临床试验的最新进展,这些临床试验调查了 PAH 特异性药物以及对心力衰竭和 PH-LHD 患者有效的药物的安全性和有效性。我们还讨论了 PH-LHD 的不同表型,以及可能参与该疾病病理生理学的分子靶点和信号通路。最后,我们将提到一些可用于治疗这种 PH 的新兴疗法。
{"title":"Pulmonary hypertension associated to left heart disease: Phenotypes and treatment","authors":"Rosalinda Madonna ,&nbsp;Filippo Biondi ,&nbsp;Sandra Ghelardoni ,&nbsp;Alberto D'Alleva ,&nbsp;Stefano Quarta ,&nbsp;Marika Massaro","doi":"10.1016/j.ejim.2024.07.030","DOIUrl":"10.1016/j.ejim.2024.07.030","url":null,"abstract":"<div><div>Pulmonary hypertension associated to left heart disease (PH-LHD) refers to a clinical and haemodynamic condition of pulmonary hypertension associated with a heterogeneous group of diseases affecting any of the compartments that form the left ventricle and left atrium. PH-LHD is the most common cause of PH, accounting for 65–80 % of diagnoses. Based on the haemodynamic phase of the disease, PH-LDH is classified into three subgroups: postcapillary PH, isolated postcapillary PH and combined pre-postcapillary PH (CpcPH). Several signaling pathways involved in the regulation of vascular tone are dysfunctional in PH-LHD, including nitric oxide, MAP kinase and endothelin-1 pathways.</div><div>These pathways are the same as those altered in PH group 1, however PH-LHD can heardly be treated by specific drugs that act on the pulmonary circulation.</div><div>In this manuscript we provide a state of the art of the available clinical trials investigating the safety and efficacy of PAH-specific drugs, as well as drugs active in patients with heart failure and PH-LHD. We also discuss the different phenotypes of PH-LHD, as well as molecular targets and signaling pathways potentially involved in the pathophysiology of the disease. Finally we will mention some new emerging therapies that can be used to treat this form of PH.</div></div>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"129 ","pages":"Pages 1-15"},"PeriodicalIF":5.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive performance of hepatocellular carcinoma risk scores in chronic hepatitis C patients with advanced fibrosis after achieving sustained virological response: Insights from European Association for the study of the Liver Policy recommendations 肝细胞癌风险评分对获得持续病毒学应答后纤维化晚期慢性丙型肝炎患者的预测性能:欧洲肝脏研究协会政策建议的启示。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-01 DOI: 10.1016/j.ejim.2024.08.018
Riham Soliman, James Lok, Saima Ajaz, Kosh Agarwal, María Guerra
{"title":"Predictive performance of hepatocellular carcinoma risk scores in chronic hepatitis C patients with advanced fibrosis after achieving sustained virological response: Insights from European Association for the study of the Liver Policy recommendations","authors":"Riham Soliman,&nbsp;James Lok,&nbsp;Saima Ajaz,&nbsp;Kosh Agarwal,&nbsp;María Guerra","doi":"10.1016/j.ejim.2024.08.018","DOIUrl":"10.1016/j.ejim.2024.08.018","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"129 ","pages":"Pages 155-157"},"PeriodicalIF":5.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1